1. Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines

   • Nino Keshelava
   • Susan Groshen
   • C. Patrick Reynolds

   ORIGINAL ARTICLE Pages: 1 - 8

2. Clinical pharmacokinetics of the irinotecan metabolite 4-piperidinopiperidine and its possible clinical importance

   • Helen M. Dodds
   • Stephen J. Clarke
   • Laurent P. Rivory

   ORIGINAL ARTICLE Pages: 9 - 14

3. Four-hourly scheduling of temozolomide improves tumour growth delay but not therapeutic index in A375M melanoma xenografts

   • Mark R. Middleton
   • Jane Kelly
   • Geoffrey P. Margison

   ORIGINAL ARTICLE Pages: 15 - 20

4. The influence of recombinant human insulin-like growth factor-I (rhIGF-I) on cell growth and cytotoxicity of drugs in childhood rhabdomyosarcoma cell lines and xenograft models

   • Corrie E.M. Gidding
   • Glen S. Germain
   • Peter J. Houghton

   ORIGINAL ARTICLE Pages: 21 - 30

5. Combined treatment of Dunning R3327 rat prostatic tumor with the 5α-reductase inhibitor PNU 157706 and the antiandrogen bicalutamide

   • Tiziana Zaccheo
   • Donata Giudici
   • Enrico di Salle

   ORIGINAL ARTICLE Pages: 31 - 37

6. Interaction between gemcitabine and mitomycin-C in vitro

   • Tu T. Aung
   • Mary A. Davis
   • Theodore S. Lawrence

   ORIGINAL ARTICLE Pages: 38 - 42

7. Sulfur-containing amino acids decrease cisplatin cytotoxicity and uptake in renal tubule epithelial cell lines

   • R. Kröning
   • A. K. Lichtenstein
   • G. T. Nagami

   ORIGINAL ARTICLE Pages: 43 - 49

8. Metabolism of camptothecin, a potent topoisomerase I inhibitor, in the isolated perfused rat liver

   • Peter Platzer
   • Theresia Thalhammer
   • Walter Jäger

   ORIGINAL ARTICLE Pages: 50 - 54

9. A pharmacokinetic and phase II study of gallium nitrate in patients with non-small cell lung cancer

   • Lorraine K. Webster
   • Ian N. Olver
   • James F. Bishop

   ORIGINAL ARTICLE Pages: 55 - 58

10. DNA guanine-guanine crosslinking sequence specificity of isophosphoramide mustard, the alkylating metabolite of the clinical antitumor agent ifosfamide

    • R. F. Struck
    • R.L. Davis Jr.
    • E. L. Loechler

    ORIGINAL ARTICLE Pages: 59 - 62

11. Variability of cyclophosphamide uptake into human bronchial carcinoma: consequences for local bioactivation

    • Frank Bohnenstengel
    • Godehard Friedel
    • Heyo K. Kroemer

    ORIGINAL ARTICLE Pages: 63 - 68

12. Potentiation of BCNU antitumor efficacy by 9-substituted O ⁶-benzylguanines. Effect of metabolism

    • D. M. Kokkinakis
    • R. C. Moschel
    • S. C. Schold

    ORIGINAL ARTICLE Pages: 69 - 77

13. Mechanism of action of the dual topoisomerase-I and -II inhibitor TAS-103 and activity against (multi)drug resistant cells

    • Hans Minderman
    • Carol Wrzosek
    • Youcef M. Rustum

    ORIGINAL ARTICLE Pages: 78 - 84

14. Phase I trial with weekly EO9, a novel bioreductive alkylating indoloquinone, by the EORTC Early Clinical Study Group (ECSG)

    • S. Aamdal
    • B. Lund
    • J. Verweij

    CLINICAL TRIAL REPORT Pages: 85 - 88

15. Lack of nephrotoxicity of new oral platinum drug JM216 in lung cancer patients

    • E. Fokkema
    • E.G.E. de Vries
    • H. J. M. Groen

    SHORT COMMUNICATION Pages: 89 - 92